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Background: Indacaterol is a novel, inhaled once-daily ultra-long-acting b2-agonist for the
treatment of COPD.
Methods: This 12-week randomised, parallel-group study compared the efficacy of indacaterol
150 mg once-daily to salmeterol 50 mg twice-daily in patients with moderate-to-severe COPD.
Assessments included FEV1 standardised area under curve (AUC) from 5 min to 11 h 45 min at
Week 12 (primary endpoint), 24-h trough FEV1 (mean of 23 h 10 min and 23 h 45 min post-dose)
at Week 12 (key secondary endpoint), FEV1 and FVC measured over 24-h, transition dyspnoea
index (TDI) and rescue medication use.
Results: Of 1123 patients randomised 92.1% completed. Mean  SD age was 62.8  8.78 years,
post-bronchodilator FEV1 51.8  12.32% predicted, FEV1/FVC 50.6  9.54%. At Week 12, FEV1
AUC5 mine11 h 45 min for indacaterol was statistically superior (p < 0.001) to salmeterol (adjusted
mean difference [95% CI] 57 [35, 79] mL), as was 24-h trough FEV1 (60 [37, 83] mL, p < 0.001).
Indacaterol also showed statistical superiority over salmeterol in terms of FEV1 and FVC
measured over 24-h at Week 12. For TDI at Week 12, the mean total score was statistically
superior for indacaterol versus salmeterol (difference 0.63 [0.30, 0.97], p < 0.001), as was
the percentage of patients with a clinically relevant (i.e., 1 point) change from baseline
(69.4% vs 62.7%, p < 0.05). For rescue medication, patients on indacaterol used fewer
puffs/day (difference 0.18 [e0.36, 0.00] puffs/day, p < 0.05) and had a greater percentage
of days with no rescue use (difference 4.4 [0.6, 8.2], p < 0.05).03 323605; fax: þ44 1403 323054.
artis.com (C. Lassen).
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720 S. Korn et al.Conclusion: Once-daily indacaterol provided statistically superior bronchodilation with an
improvement in breathlessness and rescue use compared with twice-daily salmeterol.
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Chronic obstructive pulmonary disease (COPD), is charac-
terised by a progressive development of airflow limitation
that is not fully reversible.1,2 Current treatment guidelines,
such as those from the Global Initiative for Chronic
Obstructive Lung Disease (GOLD), describe bronchodilators
as the first-line therapy for patients with moderate, severe,
and very severe COPD, with a preference for inhaled over
oral therapy.2 The algorithm for COPD maintenance treat-
ment suggests that regular use of long-acting bronchodila-
tors is more effective than treatment with short-acting
bronchodilators.2 The shift in treatment preference from
short-acting bronchodilators with multiple dosing per day
to long-acting bronchodilators with once- or twice-daily
dosing and prolonged duration of bronchodilation has
resulted in improved clinical outcomes for COPD
patients.3,4 The consequent reduction in dosing frequency
not only simplifies disease management, but has the
potential to improve patient adherence and compliance.5
Until recently, the only available long-acting b2-agonists
(LABAs) were salmeterol and formoterol, both of which
have a 12-h duration of action, and hence are used twice
daily for maintenance therapy of COPD. Now the approval
in the European Union of indacaterol, a once-daily ultra-
long-acting b2-agonist (ultra-LABA),
6 may further simplify
COPD management. In previous placebo-controlled studies,
indacaterol has demonstrated 24-h bronchodilation, with
a fast onset of action on first dose, and a good overall safety
and tolerability profile.7e10
When developing a new drug, it is useful to compare its
efficacy and safety with that of other drugs in its class. The
present study was therefore designed to compare indaca-
terol 150 mg once-daily with salmeterol 50 mg twice-daily
over 12 weeks.
Methods
This was a 12-week, multi-centre, randomised, parallel-
group, double-blind and double-dummy study. The study
was approved by the Institutional Review Board or Inde-
pendent Ethics Committee of each participating centre and
was conducted in accordance with the ethical principles
embodied in the Declaration of Helsinki (1989) and local
applicable laws and regulations. All patients provided
written informed consent prior to taking part in the study.
Selection of the study populations
The study enrolled male and female patients aged 40
years with moderate-to-severe COPD (according to the
GOLD 2007 guidelines),11 a smoking history of at least 10
pack years, and a post-bronchodilator forced expiratory
volume in 1 s (FEV1) 30% and <80% of predicted normalvalue and post-bronchodilator FEV1/forced vital capacity
(FVC) <70% at screening (the post-bronchodilator values
were measured within 10e15 min after inhaling salbutamol
400 mg). Excluded were patients with a history of asthma or
concomitant pulmonary disease; type I diabetes or uncon-
trolled type II diabetes; and cancer either active or
a history with less than 5 years disease-free survival time.
A COPD exacerbation or respiratory tract infection within 6
weeks prior to screening were also grounds for exclusion.
Study designs and treatments
The study comprised a pre-screening visit, a 14-day
screening/run-in period and a 12-week treatment period.
At the start of the 12-week treatment period, eligible
patients were randomised in a ratio of 1:1 to receive either
indacaterol 150 mg once-daily via single-dose dry powder
inhaler (taken in the morning) or salmeterol 50 mg twice-
daily (morning and evening) via the manufacturer’s
proprietary dry powder inhaler. Blinding was maintained by
providing placebo matching both treatments.
Permitted concomitant medication included inhaled
corticosteroids (ICS), if the dose and regimenwere stable for
1 month prior to screeninge the dose and regimen were also
to remain stable throughout the study. Patients previously
on fixed combinations of ICS and LABA were switched to the
equivalent ICS monotherapy at a dose and regimen main-
tained throughout the study. Salbutamol was provided for
use as needed (but not within 6 h before study assessments).
Assessments and variables
Efficacy
Spirometry was performed to measure FEV1 and FVC at the
following time points: 50 and 15 min pre-dose, and 5 min,
30 min, 1 h, 2 h, 3 h, 4 h, 8 h, 11 h 10 min and 11 h 45 min
post-dose (on Days 1, 28 and 84), and 23 h 10 min and 23 h
45 min post-dose (on Days 2, 29 and 85, based on the time
that the morning dose was taken on Days 1, 28 and 84).
The primary efficacy variable was time-standardised
area under curve (AUC) of FEV1 values between 5 min and
11 h 45 min after the morning dose at Week 12. An
exploratory subgroup analysis of the primary variable by
age, sex, smoking status, COPD severity (moderate or less
versus severe or worse), ICS use, and SABA reversibility at
screening was also performed.
The key secondary efficacy variable was trough FEV1
(defined as the mean of the FEV1 values at 23 h 10 min and
23 h 45 min following the morning dose) determined on Day
85. Trough FEV1 was also determined after the first day and
on Days 28, 29 and 84. Other secondary efficacy variables
included standardised AUC 5 mine4 h, 5 mine8 h and
8 he11 h 45 min of FEV1 at Week 12, individual time point
FEV1 on Day 1/2 and at Week 12, and individual time point
FVC measured at Week 12.
Superior efficacy of indacaterol to salmeterol 721Dyspnoea was assessed by use of the Baseline and
Transition Dyspnoea Index (BDI/TDI; recorded by a trained
assessor on a paper questionnaire), with BDI being
completed at the baseline visit, and the TDI at Week 12.
Patients recorded their daily use of rescue medication in
diaries.
Safety
Safety assessments included recording of adverse events
(AEs) and serious adverse events (SAEs), collection of
clinical laboratory data for haematology and blood chem-
istry, and monitoring of vital signs and electrocardiogram
(ECG).
Randomisation
Randomisation was performed using an automated inter-
active voice response system. Randomisation was stratified
by current use of ICSs (yes/no) and smoking status (current/
ex-smoker).
Statistical analysis
For the sample size calculation, a treatment difference of
50 mL between indacaterol and salmeterol was considered
as an important difference for COPD patients for both the
primary and the key secondary efficacy variables.9,12 To
detect this difference as statistically significant at a 5%
significance level (two sided), standard deviations of
220 mL for FEV1 standardised AUC5 mine11 h 45 min and 225 mL
for trough FEV1 were defined. Using a standard deviation of
220 mL, a total of 460 evaluable patients in each treatment
group would be needed to detect a difference in the
primary endpoint of 50 mL as statistically significant at the
5% significance level (two sided) with 93% power. For trough
FEV1, using a standard deviation of 225 mL this number of
patients would provide 92% power (86% marginal power, i.e.Table 1 Disposition of patients (n, %) during the study.
Indacaterol 150 mg od N
Patients
Screened e
Randomised 560 (100.0)
Exposed 559 (99.8)
Completed 511 (91.3)
Discontinued 49 (8.8)
Primary reason for premature
discontinuation
Adverse event(s) 20 (3.6)
Subject withdrew consent 9 (1.6)
Lost to follow-up 9 (1.6)
Protocol deviation 3 (0.5)
Abnormal lab value(s) 2 (0.4)
Unsatisfactory therapeutic effect 2 (0.4)
Death 2 (0.4)
Abnormal test procedure result(s) 1 (0.2)
Administrative problems 1 (0.2)93 %  92 %) to detect a difference of 50 mL as statistically
significant (two sided). Assuming a 15% drop out over the 12
weeks, a total of 1084 patients (542 in each treatment
group) would be needed to provide this number of evalu-
able patients.
Efficacy results are presented for the full analysis set
(FAS), which included all randomised patients who received
at least one dose of study drug. The safety results are
presented for the safety population, which included all
patients who received at least one dose of the study drug.
The primary efficacy variable was analysed using a mixed
model containing treatment as a fixed effect, with the
baseline FEV1 measurement, and FEV1 prior to and
10e15 min post inhalation of salbutamol (during the
screening visit) as covariates, with smoking status, inhaled
corticosteroid use and country as fixed effects, and centre
nested within country as a random effect. The key
secondary efficacy variable was analysed using a similar
mixed model, and Type I error was controlled for the
primary and key secondary efficacy variables. Other
secondary variables were analysed using a similar mixed
model, with no adjustment for multiplicity. For dyspnoea,
in addition to determining the mean total TDI score, the
proportion of patients with a clinically relevant (i.e., 1
point) change from baseline was analysed using logistic
regression.
Results
The study was conducted in 142 centres across 8 countries
between January and October 2009. A total of 1618
patients were screened, 1123 were randomised, and 1034
(92.1% of those randomised) completed the study. The main
reasons for premature discontinuations were AEs, with-
drawal of consent and loss to follow-up (Table 1). Demo-
graphics and baseline characteristics are summarised in
Table 2. Patients had a mean age of 62.8 years and were
predominantly male (70%) and Caucasian (84%).Z 560 Salmeterol 50 mg bid N Z 563 Total N Z 1123
e 1618
563 (100.0) 1123 (100)
562 (99.8) 1121 (99.8)
523 (92.9) 1034 (92.1)
40 (7.1) 89 (7.9)
12 (2.1) 32 (2.8)
13 (2.3) 22 (2.0)
3 (0.5) 12 (1.1)
6 (1.1) 9 (0.8)
0 2 (0.2)
2 (0.4) 4 (0.4)
1 (0.2) 3 (0.3)
1 (0.2) 2 (0.2)
2 (0.4) 3 (0.3)
Table 2 Demographics and baseline characteristics (Safety population).
Characteristics Indacaterol 150 mg
N Z 559
Salmeterol 50 mg
N Z 562
Total N Z 1121
Age (years), mean (SD) 62.4 (8.86) 63.2 (8.69) 62.8 (8.78)
Sex, n (%)
Male 370 (66.2) 415 (73.8) 785 (70.0)
Female 189 (33.8) 147 (26.2) 336 (30.0)
Race, n (%)
Caucasians 464 (83.0) 478 (85.1) 942 (84.0)
Black 19 (3.4) 11 (2.0) 30 (2.7)
Asian 71 (12.7) 68 (12.1) 139 (12.4)
Others 5 (0.9) 5 (0.9) 10 (0.9)
Duration of COPD (years), mean (SD) 6.8 (5.75) 7.4 (5.88) 7.1 (5.82)
Severity of COPD, n (%)
Moderate or less 305 (54.6) 293 (52.1) 598 (53.3)
Severe or worse 253 (45.3) 269 (47.9) 522 (46.6)
Missing 1 (0.2) 0 1 (0.1)
ICS use, n (%)
No 303 (54.2) 303 (53.9) 606 (54.1)
Yes 256 (45.8) 259 (46.1) 515 (45.9)
Smoking history, n (%)
Ex-smoker 307 (54.9) 315 (56.0) 622 (55.5)
Current smoker 252 (45.1) 247 (44.0) 499 (44.5)
Number of pack-years, mean (SD) 44.6 (23.37) 45.0 (24.27) 44.8 (23.82)
Post-bronchodilator FEV1 (% predicted), mean (SD) 52.1 (12.03) 51.5 (12.60) 51.8 (12.32)
Post-bronchodilator FEV1/FVC (%), mean (SD) 51.1 (9.08) 50.2 (9.95) 50.6 (9.54)
FEV1 reversibility (% increase), mean (SD) 14.4 (13.29) 14.4 (13.62) 14.4 (13.45)
SD Z standard deviation; ICS Z inhaled corticosteroids.
Table 3 Difference between indacaterol and salmeterol
for FEV1 standardised AUC5 mine11 h 45 min.
LS mean
treatment
difference
95% CI
Primary 57 mL*** 35, 79
Age
<65 60 mL*** 30, 90
65 52 mL** 19, 86
Sex
Male 58 mL*** 32, 85
Female 50 mL* 10, 90
Smoking status
Ex-smoker 52 mL*** 23, 82
Current smoker 63 mL*** 30, 96
COPD severity
Moderate or less 70 mL*** 40, 100
Severe or worse 40 mL* 8, 73
ICS use
No 74 mL*** 44, 104
Yes 37 mL* 5, 70
SABA reversibility
12% 39 mL* 7, 71
>12% 74 mL*** 43, 104
***p < 0.001; **p < 0.01; *p < 0.05; LS Z Least squares;
CI Z Confidence Interval.
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Primary efficacy variable
The standardised FEV1 AUC5 mine11 h 45 min at Week 12 was
statistically superior for indacaterol versus salmeterol
(p < 0.001; Table 3, primary), with an adjusted mean
difference of 57 (95% CI: 35, 79) mL. The mean (%) changes
from baseline for indacaterol and salmeterol were 0.19
(16.6%) L and 0.13 (11.4%) L, respectively. In the pre-
specified subgroup analyses, the values for indacaterol
were consistently higher than those of salmeterol (Table 3).*** ***
*** ***
–20
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Figure 1 Difference between indacaterol and salmeterol for
trough FEV1.
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Figure 2 Serial measurement of FEV1 over 24 h post-dose (a)
on Day 1/2 and (b) on Week 12.
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Trough FEV1 results were consistent with the primary effi-
cacy variable, with indacaterol showing statistical superi-
ority (p < 0.001) over salmeterol 50 mg bid at Week 12
(Fig. 1), and an adjusted mean difference of 60 (95% CI: 37,
83) mL. Indacaterol maintained statistical superiority (all
p < 0.001) over salmeterol at all visits except on Day 2
(p Z NS) (Fig. 1).
Results of the other standardised FEV1 AUC evaluations at
Week 12 supported the primary efficacy result, with inda-
caterolmaintaining statistical superiority (allp< 0.001) over
salmeterol. The adjusted mean differences were 0.06 (95%0
0.1
0.2
0.3
0.4
–2
p<0.05 for indacaterol vs salmeterol at all time points. Data are presented as unadjusted mean 
change from baseline, with p values from the associated mixed model.
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Figure 3 Serial measurement FVC over 24 h post-dose on
Week 12.CI: 0.03, 0.08) L for 5 mine4 h; 0.05 (0.03, 0.08) L for
5 mine8 h; and 0.07 (0.04, 0.09) L for 8 he11 h 45 min.
Serial measurements (unadjusted mean change from
baseline) of FEV1 over 24 h on Day 1/2 and at Week 12 (Day
84/85) are depicted in Fig. 2. At Week 12, FEV1 measure-
ments for indacaterol were statistically superior (p < 0.001)
over salmeterol at all time points including 50 and 15 min
pre-dose. On Day 1/2, indacaterol provided higher FEV1
than salmeterol at most time points, with statistical supe-
riority at six of the eleven assessments, including at 5 min
(the first post-dose assessment) and 11 h 10 min and 11 h
45 min (the two time points prior to the second adminis-
tration of salmeterol). Similarly as depicted in Fig. 3, at
Week 12 the FVC measurements for indacaterol were
statistically superior to salmeterol at all time points.
The TDI total score for indacaterol was statistically
superior (p < 0.001) to salmeterol at Week 12, with an
adjusted mean difference of 0.63 (95% CI: 0.30, 0.97). The
proportion of patients with a clinically important
improvement from baseline (1 point) in TDI total score13
followed a similar pattern, and was statistically superior
for indacaterol (69.4%) over salmeterol (62.7%), with an
odds ratio of 1.41 (95% CI 1.07, 1.85; p < 0.05).
Over the 12-week study, the use of as needed salbuta-
mol (rescue medication) was lower with indacaterol than
salmeterol. Patients in the indacaterol group used fewer
puffs/day with a mean difference of 0.18 (95% CI: 0.36,
0.00; p < 0.05) and had a greater percentage of days with
no rescue medication use, with a mean difference of 4.4
(95% CI: 0.6, 8.2; p < 0.05).
Safety
Overall incidences of AEs were similar between the treat-
ment groups; at least one AE was reported in 189/559
(33.8%) indacaterol patients and 188/562 (33.5%) salmeterol
patients, the majority being mild or moderate in severity
(Table 4). The most frequent AEs were COPD worsening
(including exacerbations; indacaterol: 25, 4.5%; salmeterol
32, 5.7%) and headache (indacaterol and salmeterol: both
20, 3.6%). Overall, 20 (3.6%) patients in the indacaterol
group experienced SAEs, compared with 16 (2.8%) patients
in the salmeterol group (Table 4). Cardiac disorders were
the most frequently reported SAEs, with 6 (1.1%) patients
experiencing eight events in the indacaterol group (three
events reported in one patient) and 2 (0.4%) patients
experiencing one event each in the salmeterol group. Of the
six patients in the indacaterol group, five patients had pre-
existing risk factors for the SAE. Three cardiac SAEs in the
indacaterol group were suspected to be study medication-
related, whilst in the salmeterol group none was suspected
to be study medication-related; of the three cases, two
patients had pre-existing cardiac risk factors. Three deaths
were reported during treatment in the study, two in the
indacaterol group, and one in the salmeterol group. One
patient, who did not receive any treatment, died during the
screening period. Of the two deaths reported in the inda-
caterol group, one patient died of a cardiopulmonary
failure, which was considered by the investigator as likely
due to gastric cancer (undiagnosed at the time of entry into
the study), whilst the cause of death for the second was
a suspected acute myocardial infarction; neither event was
Table 4 Number (%) of patients with adverse events or
serious adverse events, overall and by primary system organ
class (1% in either treatment group) (safety population).
Events Indacaterol
150 mg
od N Z 559
Salmeterol
50 mg
bid N Z 562
n (%)
Adverse events (total) 189 (33.8) 188 (33.5)
Respiratory, thoracic &
mediastinal disorders
59 (10.6) 67 (11.9)
Infections & infestations 55 (9.8) 58 (10.3)
Musculoskeletal &
connective tissue
disorders
35 (6.3) 29 (5.2)
Gastrointestinal
disorders
33 (5.9) 38 (6.8)
Nervous system
disorders
33 (5.9) 31 (5.5)
Injury, poisoning &
procedural
complications
20 (3.6) 10 (1.8)
General disorders &
administration site
conditions
18 (3.2) 16 (2.8)
Cardiac disorders 13 (2.3) 13 (2.3)
Investigations 9 (1.6) 12 (2.1)
Vascular disorders 9 (1.6) 6 (1.1)
Metabolism & nutrition
disorders
8 (1.4) 8 (1.4)
Skin & subcutaneous
tissue disorders
7 (1.3) 11 (2.0)
Blood & lymphatic
system disorders
6 (1.1) 4 (0.7)
Psychiatric disorders 6 (1.1) 14 (2.5)
Renal and urinary
disorders
1 (0.2) 7 (1.2)
Serious adverse
events (total)
20 (3.6) 16 (2.8)
Cardiac disorders 6 (1.1) 2 (0.4)
Respiratory, thoracic &
mediastinal
4 (0.7) 8 (1.4)
724 S. Korn et al.considered related to study medication. The cause of death
for the patient in the salmeterol group was respiratory
failure e again the investigator did not suspect a relation-
ship to study medication. The cause of death for the patient
who died during screening was cardiac arrest.
The proportion of patients with clinically notable values
for blood glucose (>9.99 mmol/L) was higher in the sal-
meterol group (n Z 29, 5.3%) than the indacaterol group
(nZ 16, 2.9%). During the study, a clinically notable serum
potassium value of <3.0 mmol/L was recorded only for 1
(0.2%) patient in the indacaterol group.
One patient in each treatment group had a notable pulse
rate (>130 bpm, or 120 bpm and increase from baseline
15 bpm). A notable diastolic blood pressure (>115 mmHg,
or 105 mmHg and increase from baseline 15 mmHg) was
recorded for one patient in the indacaterol group and threepatients in the salmeterol group. A notable systolic blood
pressure (>200 mmHg, or  180 mmHg and increase from
baseline of 20 mmHg) was recorded in one patient in the
indacaterol group and two patients in the salmeterol group.
A QTcF interval (i.e., QT interval corrected with Fri-
dericia’s formula) increase from baseline of >60 ms was
recorded for only one patient in the salmeterol group. None
of the patients in either treatment group had a QTcF
interval value >500 ms.
Discussion
This study was performed to evaluate the efficacy of once-
daily indacaterol versus twice-daily salmeterol in terms of
bronchodilator efficacy in patients with moderate-to-
severe COPD. The study was conducted as planned, and 92%
of the randomised patients completed the study.
Salmeterol is a LABA for twice-daily use as regular
maintenance therapy in COPD,2 thus a comparison between
salmeterol and once-daily indacaterol was of interest.
Results of a recent 14-day crossover study14 that
compared indacaterol 300 mg with open-label salmeterol
showed that indacaterol dosed once-daily has a bronchodi-
lator profile that is consistently numerically superior to sal-
meterol dosed twice-daily. A larger 26-weekcomparisonwith
blinded salmeterol suggested that in addition to improved
bronchodilator efficacy, once-daily dosingwith indacaterol is
generally more effective than twice-daily salmeterol.15
However, neither of these placebo-controlled studies (in
which salmeterol was an active comparator) had a compar-
ison of indacaterol with salmeterol as the primary objec-
tive.14,15 Therefore, this study was conducted with a power
to determine the superiority of indacaterol over salmeterol.
In terms of the bronchodilator effect, in the current
study indacaterol was statistically superior to salmeterol
with respect to standardised area under curve (AUC) of
FEV1 from 5 min to 11 h 45 min after the morning dose at
Week 12 (p < 0.001), with the treatment difference
exceeding the assumption for the important difference of
50 mL. The subgroup analyses showed consistently higher
values for indacaterol than salmeterol, suggesting that
indacaterol is effective regardless of patients’ age, sex,
smoking status, disease severity, ICS use or SABA revers-
ibility at screening. Results of FEV1 standardised AUC
measured at 5 mine4 h, 5 mine8 h and 8 he11 h 45 min at
Week 12 also showed superiority of indacaterol over sal-
meterol, with differences consistently exceeding 50 mL.
Furthermore, indacaterol demonstrated statistically supe-
rior bronchodilation compared with salmeterol in terms of
trough FEV1 at Week 12 (key secondary). It should be noted
that the trough for indacaterol was measured at 24 h post-
dose, compared with a 12 h post-dose for salmeterol. The
indacaterolesalmeterol difference (57 mL) was identical to
that seen at Week 12 in the previous 26-week placebo-
controlled study.15 In this earlier study, the trough FEV1 for
indacaterol was also statistically superior to that of sal-
meterol after 26 weeks, although not after the first day.15
This is also consistent with the current study, in which
the comparative bronchodilator efficacy of indacaterol
increased between Day 2 and Day 28, then was maintained
for the remainder of the study. However, it should be noted
that at 5 min post-dose on the first day in both studies, the
Superior efficacy of indacaterol to salmeterol 725FEV1 for indacaterol was statistically superior to that of
salmeterol, with the change from baseline with indacaterol
exceeding 100 mL (an improvement in FEV1 that can be
perceived by patients16). In contrast, the change from
baseline with salmeterol did not exceed 100 mL until 30 min
post-dose, suggesting that indacaterol has a faster onset of
action than salmeterol. This may help patients feel an
immediate symptomatic benefit e a characteristic that is
associated with increased compliance.5 Furthermore, in
a recent database analysis, the compliance with a once-
daily bronchodilator was higher than with twice-daily
bronchodilators.17 Taken together, these imply that once-
daily dosing with indacaterol could improve compliance
compared with twice-daily dosing with salmeterol.
In the current study, on regular once-daily dosing over 12
weeks there was no reduction in the bronchodilatory effi-
cacy of indacaterol; a result similar to other studies for up
to 52 weeks.7,18 In contrast, in an earlier 20-week study19
with salmeterol, a decrease in bronchodilator efficacy
was observed as early as Day 15.
Indacaterol also maintained its bronchodilatory effect as
assessed by individual time point FEV1 and FVC at Week 12,
with statistical superiority to salmeterol at all assessments,
including those in themorning. This morning improvement in
FEV1 might be beneficial, since this is when lung function is
known to be at its lowest in COPD,20 and patients are
consequently most limited by their disease.21 In addition, it
was of interest to note that both on Day 1 and Day 84 inda-
caterol showed statistical superiority (p < 0.001) over sal-
meterol in terms of FEV1 at 11 h 10 min and 11 h 45 min, just
prior to administration of the second dose of salmeterol.
One of the key disabling symptoms in COPD patients is
breathlessness,22 which results in lifestyle limitations that
often drive patients to seek medical attention. Thus,
a reduction in dyspnoea, as observed in this study, is an
important finding for indacaterol. Once-daily indacaterol
was statistically superior to twice-daily salmeterol, both in
terms of the mean TDI total scores and the percentage of
patients with a clinically relevant (1 point) change from
baseline. Indacaterol also allowed patients more days
without rescue medication, with patients in the indacaterol
group also using fewer puffs per day of rescue salbutamol.
Thresholds for clinical relevance between two active
treatments have not been defined for these parameters.
Therefore, one must be careful when interpreting the clin-
ical relevance of these statistically significant differences.
Both treatments were similarly well tolerated, with the
majority of AEs being mild or moderate in severity. This
observation was similar to a previous 1-year study which
compared higher doses (300 mg and 600 mg) of indacaterol
with placebo and formoterol.7 In the current study slightly
more SAEs were experienced by patients in the indacaterol
group than in the salmeterol group, with most of them
being related to cardiac disorders. However, of the three
cardiac SAEs suspected to be study medication-related, two
patients had pre-existing risk factors, which might have
contributed to the cardiac SAEs. There was no evidence of
any clinically meaningful effect of either treatment on
potassium or glucose levels, nor was there a significant
effect of either treatment on vital signs or the ECG
assessments. Overall, indacaterol 150 mg once-daily showed
a good safety profile and was well tolerated.Conclusion
Indacaterol 150 mg once-daily provides statistically superior
bronchodilation over salmeterol 50 mg twice-daily, with the
efficacy being sustained for 24 h post-dose even after 12
weeks of treatment. This study also showed that indaca-
terol reduces breathlessness and use of rescue medication
compared to salmeterol. Therefore, once-daily dosing with
indacaterol treatment may provide COPD patients with
a useful treatment option.Acknowledgements
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